

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51

RRID:AB_394763

Type: Antibody

Proper Citation

BD Biosciences Cat# 553294, RRID:AB_394763

Antibody Information

URL: http://antibodyregistry.org/AB_394763

Proper Citation: BD Biosciences Cat# 553294, RRID:AB_394763

Target Antigen: CD28

Clonality: monoclonal

Comments: Flow cytometry, Immunohistochemistry-frozen

Antibody Name: Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: 37.51

Antibody ID: AB_394763

Vendor: BD Biosciences

Catalog Number: 553294

Record Creation Time: 20250820T042753+0000

Record Last Update: 20250820T190227+0000

Ratings and Alerts

No rating or validation information has been found for Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51.

No alerts have been found for Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 58 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Zhao CN, et al. (2025) *Phocaeicola vulgatus* induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. *Cell reports. Medicine*, 102370.

Wu Y, et al. (2025) DA-DRD5 signaling reprograms B cells to promote CD8+ T cell-mediated antitumor immunity. *Cell reports*, 44(3), 115364.

Osaki M, et al. (2025) Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. *Immunity*, 58(4), 889.

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. *Cell*, 188(9), 2372.

Rao C, et al. (2025) Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of type 1 diabetes. *Diabetologia*, 68(2), 382.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. *Cell*.

Li J, et al. (2025) Monocyte/macrophage-derived interleukin-15 mediates the pro-inflammatory phenotype of CD226+ B cells in type 1 diabetes. *EBioMedicine*, 120, 105946.

Rao C, et al. (2024) Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of Type 1 Diabetes. *bioRxiv : the preprint*

server for biology.

Ichiyama K, et al. (2024) Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity. *Immunity*, 57(9), 2043.

Meza-Perez S, et al. (2024) Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine. *Cell host & microbe*, 32(7), 1177.

Martins C, et al. (2024) Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling. *Science advances*, 10(3), eadi2012.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. *Immunity*, 57(2), 287.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. *Immunity*, 57(12), 2863.

Bülow S, et al. (2024) Bactericidal/permeability-increasing protein instructs dendritic cells to elicit Th22 cell response. *Cell reports*, 43(3), 113929.

Baldwin JG, et al. (2024) Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. *Cell*.

Nian Z, et al. (2024) Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. *Immunity*, 57(10), 2344.

Nava Lauson CB, et al. (2023) Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. *Cell metabolism*, 35(4), 633.

Sandner L, et al. (2023) The guanine nucleotide exchange factor Rin-like controls Tfh cell differentiation via CD28 signaling. *The Journal of experimental medicine*, 220(11).